The JAK/STAT inhibitor tofacitinib, recently approved for the treatment of ulcerative colitis, is found to modulate the intestinal endothelial barrier functions in directing the leukocyte adhesion and transmigration in ulcerative colitis patients displaying high levels of endothelial STAT3/STAT6 phosphorylation.
Tofacitinib Inhibits Leukocyte Trafficking Across the Intestinal Endothelial Barrier in a Specific Cohort of Ulcerative Colitis Patients / Massimino, L.; Spano, S.; Lamparelli, L. A.; Fuggetta, D.; Peyrin-Biroulet, L.; Sileri, P.; Danese, S.; D'Alessio, S.; Ungaro, F.. - In: INFLAMMATORY BOWEL DISEASES. - ISSN 1078-0998. - 28:6(2022), pp. 971-976. [10.1093/ibd/izab349]
Tofacitinib Inhibits Leukocyte Trafficking Across the Intestinal Endothelial Barrier in a Specific Cohort of Ulcerative Colitis Patients
Sileri P.;Danese S.;
2022-01-01
Abstract
The JAK/STAT inhibitor tofacitinib, recently approved for the treatment of ulcerative colitis, is found to modulate the intestinal endothelial barrier functions in directing the leukocyte adhesion and transmigration in ulcerative colitis patients displaying high levels of endothelial STAT3/STAT6 phosphorylation.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
